Tekturna

Quote












Anonymous said:
Novartis has the best MC Team in the nation.

Tekturna, like all new products, was tier 2 after just 3 weeks.
Click to expand...

Doesn't matter what tier TKT is. It could be tier 1 and it still wouldn't be moving like it currently isnt. You see, products move when they are valued by prescribers. Without outcomes data, it has no reason to be written before all the other tried and true htn drugs. Novartis blew this launch by coming out with mild - moderate data. It has a perception of being weak, efficacy wise. You have to lauch with severe data to give the impression of power. Definitely a miscalculation by the brand team. Now, the only thing that will save Aliskiren is some significant outcomes data. Its a big gamble now.
 






so the reduction of renin,PRA,Ang l and ll have no significance ? What about the value in the diabetic patient ? Doesnt that patient type struggle suppressing RAAS activity ? I thought ACE, ARB showed a increase in PRA and aliskiren showed a decrease across the board. ??
 






Anonymous said:
so the reduction of renin,PRA,Ang l and ll have no significance ? What about the value in the diabetic patient ? Doesnt that patient type struggle suppressing RAAS activity ? I thought ACE, ARB showed a increase in PRA and aliskiren showed a decrease across the board. ??
Click to expand...

GOOD GRIEF you buy into this marketing SPIN ? LMAO !!!
You wonder why tekturkey reduces BP like a placebo ?
Probably because it binds to a MINUTE % of renin.

Face it , it's garbage through & through & no amount of honarariums
& one sided studies will change that

They should have called it Starlix II

You should be ashamed to have a tiny % of doctors dupe patients with this crap !
 






Anonymous said:
so the reduction of renin,PRA,Ang l and ll have no significance ? What about the value in the diabetic patient ? Doesnt that patient type struggle suppressing RAAS activity ? I thought ACE, ARB showed a increase in PRA and aliskiren showed a decrease across the board. ??
Click to expand...

1st, Tekturna doesn't cause a reduction of renin. In fact it actually increases the production of renin. 2nd, the clinical implications of differences in effect on RAAS components are not known. That comes directly from our vis aid. Until aliskiren gets outcomes data, it will never be used 1st line. We're trying to set up a problem that may be there, but the solution is not...at least not just yet.
 






as a direct renin inhibitor,it decreases plasma renin activity and inhibits the conversion of angiotensinogen to Ang 1...and eventually less Ang 2, but if the increased renin levels are blocked i thought there would be less renin, not increased renin ?
 






Anonymous said:
1st, Tekturna doesn't cause a reduction of renin. In fact it actually increases the production of renin. 2nd, the clinical implications of differences in effect on RAAS components are not known. That comes directly from our vis aid. Until aliskiren gets outcomes data, it will never be used 1st line. We're trying to set up a problem that may be there, but the solution is not...at least not just yet.
Click to expand...

I hope the FDA takes Novartis down for this one...diabetic hypertensive patient what data?
 












science ? oh please. come to the state of Minn. and sell science,phys. find it interesting and dont disagree but driving prescriptions is manage care controlled. insurance company have no interest in the science or a phys rational. its generic first,generic plus hct second,and then its documentation/PA to get your third line which may be a drug like tekturna. time is money and dealing with ins. companies loses them money. if you can get a phys. to agree and get into a habit to use tekturna third line, you will look like a champ in Minn.
 






Remember the lying cheating disgusting N7 sales force that sold the drug when it came out? Blame them for the problems. Look at them, all of them. Even the ones who left the company or who were promoted.
 






Tekturna is doing great in my territory. I'm glad the incentive is on the family and not on the new products. I think the story is really taking off. It may not replace Diovan but it's pretty good.
 






I would love to hear your story. In theory it makes sense but phys. arent prescribing on theory. They question its documented benefit compared to established products. In addition the insurance companies are requiring lisinopril first, then losartan, if more needed amlodipine before adding a branded choice.

So please share the specifics of your detail. We may learn something.
 






Physicians are being incentivized to prescribe based on Evidence Based outcome data which directly impacts their scorecards and p4p with third party payers. Look up HEDIS and PQRS and you will see why they are not rxing Tekturna. Tekturna has no evidence of improved outcomes at this time....
 






Top Bottom
Back
Quote